2025
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study
Morales D, Bu F, Viernes B, DuVall S, Matheny M, Simon K, Falconer T, Richter L, Ostropolets A, Lau W, Man K, Chattopadhyay S, Mathioudakis N, Minty E, Nishimura A, Sun F, Yin C, Seager S, Chai Y, Zhou J, Lu Y, Reyes C, Pistillo A, Duarte-Salles T, Blacketer C, Schuemie M, Ryan P, Krumholz H, Hripcsak G, Khera R, Suchard M. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care 2025, 48: 1386-1394. PMID: 40465422, PMCID: PMC12281980, DOI: 10.2337/dc25-0154.Peer-Reviewed Original ResearchRisk of thyroid tumorThyroid tumorsGLP-1RADPP-4isHazard ratioThyroid malignancyCohort studyIncreased riskSodium-glucose cotransporter 2 inhibitorsElectronic health record databaseGlucagon-like peptide 1 receptor agonistsEstimate hazard ratiosRandom-effects meta-analysisGLP-1 receptor agonistsPeptide 1 receptor agonistsDipeptidyl peptidase 4 inhibitorsThyroid tumor incidenceUsers of SGLT2isHealth record databaseSecond-line treatmentType 2 diabetes mellitusNew-user cohort studyRetrospective cohort studyUsers of sulfonylureasIntention-to-treatRisk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study
Janetzki J, Kim J, Minty E, Lee J, Morales D, Khera R, Kim C, Alshammari T, DuVall S, Matheny M, Falconer T, Kim S, Phan T, Nguyen P, Hsu M, Hsu J, Park R, Man K, Seager S, Van Zandt M, Gilbert J, Ryan P, Schuemie M, Suchard M, Hripcsak G, Pratt N, You S. Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study. EClinicalMedicine 2025, 81: 103096. PMID: 39975698, PMCID: PMC11836508, DOI: 10.1016/j.eclinm.2025.103096.Peer-Reviewed Original ResearchUrinary tract infectionRisk of aortic aneurysmTreat urinary tract infectionsOutpatient settingAortic aneurysmIndex dateCohort studyHazard ratioUrinary tract infection treatmentYonsei University College of MedicineRetrospective cohort studyPropensity scoreCox proportional hazards modelsPropensity-matched pairsRandom-effects meta-analysisProportional hazards modelNational Health and Medical Research Council (NHMRCUniversity College of MedicineSystemic fluoroquinolonesTract infectionsNo significant differenceBayesian random-effects meta-analysisFollow-upPrimary outcomeIncreased risk
2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, PMCID: PMC12045554, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply